The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McKallip, R.
Right arrow Articles by Ladisch, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKallip, R.
Right arrow Articles by Ladisch, S.
The Journal of Immunology, 1999, 163: 3718-3726.
Copyright © 1999 by The American Association of Immunologists

Tumor Gangliosides Inhibit the Tumor-Specific Immune Response1

Robert McKallip, Ruixiang Li and Stephan Ladisch2

Glycobiology Program, Center for Cancer and Transplantation Biology, Children’s National Medical Center, and Departments of Pediatrics and Biochemistry/Molecular Biology, George Washington University School of Medicine,Washington, DC 20010

Tumor gangliosides are highly immunosuppressive membrane glycosphingolipids that are shed into the tumor cell microenvironment. We directly tested the impact of shed gangliosides on the in vivo antitumor immune response in a syngeneic fully autochthonous system (FBL-3 erythroleukemia cells, C57BL/6 mice, and highly purified FBL-3 cell gangliosides). The major FBL-3 ganglioside was identified as GM1b by mass spectrometry. Substantial ganglioside shedding (90 pmol/108 cells/h), a requisite for their inhibition of the immune function of tumor-infiltrating leukocytes, was detected. Immunosuppression by FBL-3 gangliosides was potent; 5–20 µM inhibited the tumor-specific secondary proliferative response (80–100%) and suppressed the generation of tumor-specific CTLs (97% reduction of FBL-3 cell lysis at an E:T ratio of 100:1). In vivo, coinjection of 10 nmol of FBL-3 gangliosides with a primary FBL-3 cell immunization led to a reduced response to a secondary challenge (the increase in the draining popliteal lymph node mass, cell number, and lymphocyte thymidine incorporation were lowered by 70, 69, and 72%, respectively). Coinjection of gangliosides with a secondary tumor challenge led to a 61, 74, and 42% reduction of the increase in lymph node mass, cell number, and thymidine uptake and a 63–74% inhibition of the increase of draining lymph node T cells (CD3+), B cells (CD19+), and dendritic cells/macrophages (Mac-3+). Overall, the clear conclusion that tumor-derived gangliosides inhibit syngeneic antitumor immune responses implicates these molecules as a potent factor in promoting tumor formation and progression.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Biswas, K. Biswas, A. Richmond, J. Ko, S. Ghosh, M. Simmons, P. Rayman, B. Rini, I. Gill, C. S. Tannenbaum, et al.
Elevated Levels of Select Gangliosides in T Cells from Renal Cell Carcinoma Patients Is Associated with T Cell Dysfunction
J. Immunol., October 15, 2009; 183(8): 5050 - 5058.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
K. Bennaceur, I. Popa, J. A. Chapman, C. Migdal, J. Peguet-Navarro, J.-L. Touraine, and J. Portoukalian
Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells
Glycobiology, June 1, 2009; 19(6): 576 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. de Leon, A. Fernandez, M. Clavell, M. Labrada, Y. Bebelagua, C. Mesa, and L. E. Fernandez
Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function
Int. Immunol., April 1, 2008; 20(4): 591 - 600.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Shen, K. Stone, A. Jales, D. Leitenberg, and S. Ladisch
Inhibition of TLR Activation and Up-Regulation of IL-1R-Associated Kinase-M Expression by Exogenous Gangliosides
J. Immunol., April 1, 2008; 180(7): 4425 - 4432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Das, G. Sa, C. Hilston, D. Kudo, P. Rayman, K. Biswas, L. Molto, R. Bukowski, B. Rini, J. H. Finke, et al.
GM1 and Tumor Necrosis Factor-{alpha}, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
Cancer Res., March 15, 2008; 68(6): 2014 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al.
TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction
J. Immunol., May 15, 2007; 178(10): 6642 - 6652.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. Hamada, M. K. Kim, A. Iwakura, M. Ii, T. Thorne, G. Qin, J. Asai, Y. Tsutsumi, H. Sekiguchi, M. Silver, et al.
Estrogen Receptors {alpha} and {beta} Mediate Contribution of Bone Marrow-Derived Endothelial Progenitor Cells to Functional Recovery After Myocardial Infarction
Circulation, November 21, 2006; 114(21): 2261 - 2270.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Biswas, A. Richmond, P. Rayman, S. Biswas, M. Thornton, G. Sa, T. Das, R. Zhang, A. Chahlavi, C. S. Tannenbaum, et al.
GM2 Expression in Renal Cell Carcinoma: Potential Role in Tumor-Induced T-Cell Dysfunction.
Cancer Res., July 1, 2006; 66(13): 6816 - 6825.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. Bennaceur, I. Popa, J. Portoukalian, O. Berthier-Vergnes, and J. Peguet-Navarro
Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis
Int. Immunol., June 1, 2006; 18(6): 879 - 886.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. A. Crespo, X. Sun, J. G. Cripps, and R. Fernandez-Botran
The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses
J. Leukoc. Biol., March 1, 2006; 79(3): 586 - 595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Shen, R. Falahati, R. Stark, D. Leitenberg, and S. Ladisch
Modulation of CD4 Th Cell Differentiation by Ganglioside GD1a In Vitro
J. Immunol., October 15, 2005; 175(8): 4927 - 4934.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. L. Tourkova, G. V. Shurin, G. S. Chatta, L. Perez, J. Finke, T. L. Whiteside, S. Ferrone, and M. R. Shurin
Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides
J. Immunol., September 1, 2005; 175(5): 3045 - 3052.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Kotlan, P. Simsa, J.-L. Teillaud, W. H. Fridman, J. Toth, M. McKnight, and M. C. Glassy
Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes
J. Immunol., August 15, 2005; 175(4): 2278 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Cancer Res., June 15, 2005; 65(12): 5428 - 5438.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al.
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses
Clin. Cancer Res., September 15, 2004; 10(18): 6360S - 6366S.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Y.-Y. Liu, T. Y. Han, J. Y. Yu, A. Bitterman, A. Le, A. E. Giuliano, and M. C. Cabot
Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells
J. Lipid Res., May 1, 2004; 45(5): 933 - 940.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al.
Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas
J. Immunol., March 15, 2004; 172(6): 3480 - 3490.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
X. Zhang and F. L. Kiechle
Glycosphingolipids in Health and Disease
Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 3 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. Kishore, C. Luedemann, E. Bord, D. Goukassian, and D. W. Losordo
Tumor Necrosis Factor-Mediated E2F1 Suppression in Endothelial Cells: Differential Requirement of c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Signal Transduction Pathways
Circ. Res., November 14, 2003; 93(10): 932 - 940.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Draberova, L. Dudkova, M. Boubelik, H. Tolarova, F. Smid, and P. Draber
Exogenous Administration of Gangliosides Inhibits Fc{epsilon}RI-Mediated Mast Cell Degranulation by Decreasing the Activity of Phospholipase C{gamma}
J. Immunol., October 1, 2003; 171(7): 3585 - 3593.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Caldwell, A. Heitger, W. Shen, Y. Liu, B. Taylor, and S. Ladisch
Mechanisms of Ganglioside Inhibition of APC Function
J. Immunol., August 15, 2003; 171(4): 1676 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Saito, H. Aoki, A. Ito, S. Ueno, T. Wada, K. Mitsuzuka, M. Satoh, Y. Arai, and T. Miyagi
Human {alpha}2,3-Sialyltransferase (ST3Gal II) Is a Stage-specific Embryonic Antigen-4 Synthase
J. Biol. Chem., July 11, 2003; 278(29): 26474 - 26479.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke
Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells
Cancer Res., April 1, 2003; 63(7): 1676 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Peguet-Navarro, M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian
Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis
J. Immunol., April 1, 2003; 170(7): 3488 - 3494.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Sriram, S. Cho, P. Li, P. W. O'Donnell, C. Dunn, K. Hayakawa, J. S. Blum, and R. R. Brutkiewicz
Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells
PNAS, June 11, 2002; 99(12): 8197 - 8202.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
W. Deng, R. Li, M. Guerrera, Y. Liu, and S. Ladisch
Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation
Glycobiology, March 1, 2002; 12(3): 145 - 152.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. Deng, R. Li, and S. Ladisch
Influence of Cellular Ganglioside Depletion on Tumor Formation
J Natl Cancer Inst, June 7, 2000; 92(11): 912 - 917.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.